Selma Ugurel

Selma Ugurel

Essen, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 224 publications

Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study.

Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 25, 2026

Treatment patterns in geriatric patients with melanoma and the effect of age on the efficacy of immunotherapy: Analysis from the real-world multicenter registry ADOREG.

Treatment patterns in geriatric patients with melanoma and the effect of age on the efficacy of immunotherapy: Analysis from the real-world multicenter registry ADOREG.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 16, 2026

Merkel cell carcinoma immunotherapy: key questions in the era of immune checkpoint blockade.

Merkel cell carcinoma immunotherapy: key questions in the era of immune checkpoint blockade.

Journal: Journal for immunotherapy of cancer

Published: December 29, 2025

Tumor immune microenvironment remodeling predicts response to checkpoint inhibitor therapy.

Tumor immune microenvironment remodeling predicts response to checkpoint inhibitor therapy.

Journal: Cancer cell

Published: November 24, 2025

Extracorporeal photopheresis as a therapeutic approach for treatment resistant immune-related adverse events in anti-PD-1-treated melanoma patients.

Extracorporeal photopheresis as a therapeutic approach for treatment resistant immune-related adverse events in anti-PD-1-treated melanoma patients.

Journal: Frontiers in immunology

Published: October 17, 2025

Enhanced overall and progression-free survival in advanced melanoma patients undergoing targeted therapy alongside antithrombotic treatment - Insights from a multicenter study involving 1296 patients from the prospective skin cancer registry ADOReg.

Enhanced overall and progression-free survival in advanced melanoma patients undergoing targeted therapy alongside antithrombotic treatment - Insights from a multicenter study involving 1296 patients from the prospective skin cancer registry ADOReg.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 12, 2025

S1 guideline sweat gland carcinoma.

S1 guideline sweat gland carcinoma.

Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

Published: September 28, 2025

Tertiary lymphoid structures in Merkel cell carcinoma facilitate naïve and central memory T-cell infiltration linked to immunotherapy response.

Tertiary lymphoid structures in Merkel cell carcinoma facilitate naïve and central memory T-cell infiltration linked to immunotherapy response.

Journal: Journal for immunotherapy of cancer

Published: August 24, 2025

Melanoma of unknown primary shows an oncogenic pattern and clinical course of sun-exposed melanoma.

Melanoma of unknown primary shows an oncogenic pattern and clinical course of sun-exposed melanoma.

Journal: The British journal of dermatology

Published: August 06, 2025

Outcome of systemic therapy in patients with advanced rare skin cancers: A retrospective multicenter DeCOG study of 209 patients.

Outcome of systemic therapy in patients with advanced rare skin cancers: A retrospective multicenter DeCOG study of 209 patients.

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 03, 2025

Role of comorbidities and medication on immunotherapy efficacy in cSCC: A DeCOG multicentre analysis.

Role of comorbidities and medication on immunotherapy efficacy in cSCC: A DeCOG multicentre analysis.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: July 31, 2025

Long-Term Follow-Up of Real-World Adjuvant Anti-PD-1 Checkpoint Inhibition and Targeted Therapy in Patients With Stage III Melanoma.

Long-Term Follow-Up of Real-World Adjuvant Anti-PD-1 Checkpoint Inhibition and Targeted Therapy in Patients With Stage III Melanoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 03, 2025

Showing 1-12 of 224

Last Updated: 09/26/2026